Aquestive Therapeutics Inc AQST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
-
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST
-
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
-
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Pattern Of Harm: SueWallSt
-
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Stock Dropped Over 37 Percent: Levi & Korsinsky
-
Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
-
AQST Deadline: AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
Trading Information
- Previous Close Price
- $4.21
- Day Range
- $4.17–4.30
- 52-Week Range
- $2.93–7.55
- Bid/Ask
- $4.14 / $4.30
- Shares Outstanding
- 125.45M
- Market Cap
- $523.13M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 147
- Website
- https://www.aquestive.com
Valuation
|
Metric
|
AQST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 9.52 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AQST
|
|---|---|
Quick Ratio | 3.70 |
Current Ratio | 4.10 |
Interest Coverage | −3.34 |
Quick Ratio
AQST
Profitability
|
Metric
|
AQST
|
|---|---|
Return on Assets (Normalized) | −45.80% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −15,994.28% |
Return on Assets
AQST
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Lxbcnmhcx | Bttwxqj | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Jrpxnfsbcy | Dsdktg | $40B | |||
| Haleon PLC ADR
HLN
| Vgxyvzx | Nnv | $40B | |||
| Zoetis Inc Class A
ZTS
| Pzhcsqtzv | Cgwc | $33B | |||
| Viatris Inc
VTRS
| Typmtmvv | Yfm | $19B | |||
| Elanco Animal Health Inc
ELAN
| Lbp | Wfsg | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Rhtpcwq | Vtfkq | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Mbkvlmv | Tlzb | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| Bzfhpdv | Mbnbrm | $2B | |||
| Perrigo Co PLC
PRGO
| Dccxztfwf | Kdlmg | $2B |
United States